IL-1β can be considered as both pro- and anti-tumoral; that is, it promotes anti-tumour responses via its pro-inflammatory nature and its ability to promote Th17 differentiation and neutrophil activation and it is also able to drive pro-tumour responses via tumour invasiveness and immunosuppression [44,45]. The gene discussed is IL1B; the disease is neoplasm.